TC BioPharm (Holdings) Stock Price, News & Analysis

TC BioPharm (Holdings) PLC (traded in the U.S. over-the-counter market under the symbol TCBPY) is described as a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gamma-delta T cell therapies for cancer treatment. According to company disclosures, it is a clinical-stage biotechnology business developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, with human efficacy data in acute myeloid leukemia.

Gamma-delta T cells are characterized in the company’s materials as naturally occurring immune cells that combine properties of both the innate and adaptive immune systems and can intrinsically distinguish between healthy and diseased tissue. TC BioPharm states that it is focused on using these cells as the basis for therapeutic products, including allogeneic approaches intended to provide frozen product to clinics.

Business focus and therapeutic platform

The company describes itself as developing a platform of allogeneic gamma-delta T cell therapies. Its disclosures refer to a product line of unmodified gamma-delta T cells and a proprietary allogeneic technology called CryoTC, which is intended to provide frozen product for clinical use worldwide. TC BioPharm reports that it has human efficacy data in acute myeloid leukemia and that it is conducting investigator-initiated clinical trials using its unmodified gamma-delta T cell products.

According to the company, it is conducting a Phase 2b/3 pivotal trial in the treatment of acute myeloid leukemia using its CryoTC technology. The company’s communications also state that it has undertaken phase II/pivotal clinical studies in oncology and that it is focused on gamma-delta T cell therapies for cancer treatment, with additional interest in microbial and viral indications.

Intellectual property and European patent

TC BioPharm has reported the grant of a patent from the European Patent Office for targeting microbial, oncological, and viral indications using modified gamma-delta T cells. The company indicates that this patent relates to refining the targeting of modified gamma-delta T cells so that they can be applied to a broad spectrum of indications while aiming to mitigate toxicity risks associated with modified cell therapies. It has stated an intention to proceed with the patent process in specific European countries in line with its commercial strategy.

In its public statements, TC BioPharm links this patent to an expanding patent portfolio that it believes secures the future development of its assets based on gamma-delta T cell technology. The focus of this intellectual property is described as targeting microbial, oncological, and viral indications using modified gamma-delta T cells.

Clinical development activities

The company reports that it is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line. One of these is described as a Phase 2b/3 pivotal trial in acute myeloid leukemia, using the CryoTC allogeneic technology to supply frozen product to clinics. These activities position TC BioPharm as a clinical-stage entity, with its main efforts centered on oncology and gamma-delta T cell–based therapeutics.

TC BioPharm also describes itself as the first company to conduct phase II/pivotal clinical studies in oncology using gamma-delta T cell therapies. This characterization is presented in its own communications about its role in the gamma-delta T cell therapy space.

Corporate and regulatory status

TC BioPharm (Holdings) PLC is identified in SEC filings as a foreign private issuer with a Commission File Number of 001-41231. Its American Depositary Shares (ADSs), each representing a specified number of ordinary shares, were registered under the Securities Exchange Act of 1934. Subsequent filings describe significant changes to its regulatory and corporate status.

In a Form 6-K, the company reported that on November 10, 2025, its directors resolved to appoint interim liquidators to TC BioPharm (Holdings) PLC. The same filing stated that the company intended to file a Form 15 with the U.S. Securities and Exchange Commission to deregister its American Depositary Shares under the Exchange Act, with the company’s obligation to file periodic reports to be suspended upon that filing.

A later Form 15 certification and notice of termination of registration under Section 12(g) and suspension of duty to file reports under Sections 13 and 15(d) of the Exchange Act was filed, identifying TC BioPharm (Holdings) PLC and its American Depositary Shares. This filing indicates that the company has terminated the registration of that class of securities and suspended its duty to file periodic reports under the Exchange Act.

Another Form 6-K describes that on October 2, 2025, the directors of TC BioPharm Limited, a subsidiary of TC BioPharm (Holdings) PLC, appointed joint administrators to TC BioPharm Limited, with those administrators exploring options for the sale of the business and assets of the subsidiary, including intellectual property and R&D assets, for the benefit of creditors. That filing also states that TC BioPharm (Holdings) PLC continued to operate as usual outside of the administration process at that time.

Implications for investors and ticker status

The Form 15 filing confirms that TC BioPharm (Holdings) PLC has terminated the registration of its American Depositary Shares under the Securities Exchange Act of 1934 and suspended its duty to file periodic reports with the SEC. This indicates that TCBPY, as an ADS representing ordinary shares of TC BioPharm (Holdings) PLC, is no longer registered under Section 12(g) of the Exchange Act. While the filings describe deregistration and the appointment of interim liquidators, they do not, by themselves, describe how or whether the ADSs or underlying shares may trade on any particular market after deregistration.

Users reviewing information about TCBPY should be aware that the company has reported the appointment of interim liquidators and has filed Form 15 to deregister its ADSs. These steps are material to understanding the regulatory and corporate context for this security and suggest that TC BioPharm is in a form of liquidation or wind-down process as described in its filings.

Summary of sector and focus

Within the healthcare sector and biotechnology industry, TC BioPharm (Holdings) PLC describes its focus as gamma-delta T cell–based therapies, with an emphasis on oncology and acute myeloid leukemia, and with additional indications in microbial and viral areas referenced in its patent disclosures. Its activities, as described in company communications and SEC filings, combine clinical-stage development, investigator-initiated trials, and the development and protection of intellectual property around gamma-delta T cell technologies, alongside significant later-stage corporate events such as administration of a subsidiary, appointment of interim liquidators, and deregistration of its ADSs.